Provided is an immunostimulator containing: chitosan and/or a chitosan derivative each having a weight-average molecular weight of 10k to 1000k; and an anionic surfactant, the immunostimulator being in particulate form. Also provided are a pharmaceutical composition and an alimentary product, each containing the immunostimulator as an active ingredient.

In various aspects, the present disclosure pertains to methods of treating or preventing bleeding at a tissue site comprising applying a chitosan powder composition to the tissue site. In various aspects, the present disclosure pertains to chitosan powder compositions for application to a tissue site, where the powder compositions comprise a chitosan salt, a crosslinked chitosan, a derivatized chitosan, or a combination thereof. In various aspects, the disclosure pertains to catheter assemblies, which are preloaded with a chitosan powder composition and which are configured to deliver the chitosan powder composition a tissue site.

In various aspects, the present disclosure pertains to methods of treating or preventing bleeding at a tissue site comprising applying a chitosan powder composition to the tissue site. In various aspects, the present disclosure pertains to chitosan powder compositions for application to a tissue site, where the powder compositions comprise a chitosan salt, a crosslinked chitosan, a derivatized chitosan, or a combination thereof. In various aspects, the disclosure pertains to catheter assemblies, which are preloaded with a chitosan powder composition and which are configured to deliver the chitosan powder composition a tissue site.

Provided herein are methods of treating (e.g., inhibiting, modulating, reversing, or reducing the severity of at least one symptom of) a dysbiosis in a subject, the method comprising administering an effective amount of a composition described herein (e.g., a composition comprising polyglucosamine-arginine (PAAG)).

Provided herein are methods of treating (e.g., inhibiting, modulating, reversing, or reducing the severity of at least one symptom of) a dysbiosis in a subject, the method comprising administering an effective amount of a composition described herein (e.g., a composition comprising polyglucosamine-arginine (PAAG)).

The present invention relates to an acetylated amphiphilic carbohydrate compound of average molecular weight 1-50 kDa which is based on a glycol chitosan, wherein the levels of acetylation can be modified. The compound can be formulated with hydrophobic compounds such as drugs. The degree of acetylation of the carbohydrate compound is optimised to maximise solubilisation of the drugs. The compound is formulated with drugs and is useful in therapy.

The present invention relates to an acetylated amphiphilic carbohydrate compound of average molecular weight 1-50 kDa which is based on a glycol chitosan, wherein the levels of acetylation can be modified. The compound can be formulated with hydrophobic compounds such as drugs. The degree of acetylation of the carbohydrate compound is optimised to maximise solubilisation of the drugs. The compound is formulated with drugs and is useful in therapy.

The present invention relates to an acetylated amphiphilic carbohydrate compound of average molecular weight 1-50 kDa which is based on a glycol chitosan, wherein the levels of acetylation can be modified. The compound can be formulated with hydrophobic compounds such as drugs. The degree of acetylation of the carbohydrate compound is optimised to maximise solubilisation of the drugs. The compound is formulated with drugs and is useful in therapy.

The present invention relates to a method for the large-scale synthesis of an edible and hot steam sterilizable macroporous three-dimensional (3D) scaffold which comprises biocompatible polymers with interconnected pores as a support material for adherent cell growth, proliferation and differentiation, which may be used to obtain tissue with nutritive content and/or cultured meat. These scaffolds are suitable for supporting cell tissue growth for biomedical or food applications.

A composition in powder form comprising alginic acid or sodium alginate, -pectin and chitosan, wherein the % by weight of the polysaccharides is at least 20% with respect to the total weight of the powder, the process for preparing the powder and its use in the treatment of cutaneous wounds and in the sector of food preservation are described.